E-viri
Recenzirano
Odprti dostop
-
Guisado-Vasco, Pablo; Valderas-Ortega, Sofia; Carralón-González, Maria Maravillas; Roda-Santacruz, Ana; González-Cortijo, Lucia; Sotres-Fernández, Gabriel; Martí-Ballesteros, Eva María; Luque-Pinilla, José Manuel; Almagro-Casado, Elena; La Coma-Lanuza, Félix J.; Barrena-Puertas, Ruth; Malo-Benages, Esteban Javier; Monforte-Gómez, María José; Diez-Munar, Rocío; Merino-Lanza, Esther; Comeche-Casanova, Lorena; Remirez-de-Esparza-Otero, Margarita; Correyero-Plaza, María; Recio-Rodríguez, Manuel; Rodríguez-López, Margarita; Sánchez-Manzano, María Dolores; Andreu-Vázquez, Cristina; Thuissard-Vasallo, Israel John; María-Tomé, José María Echave-Sustaeta; Carnevali-Ruiz, Daniel
EClinicalMedicine, 11/2020, Letnik: 28Journal Article
The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available therapies (antimalarials, antivirals, biological agents) were grounded on clinical case observations or basic science data. The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients. In this retrospective, single-center, observational study, we collected sequential data on adult patients admitted to Hospital Universitario Quironsalud Madrid. Eligible patients should have a microbiological (positive test on RT-PCR assay from a nasal swab) or an epidemiological diagnosis of severe COVID-19. Demographic, baseline comorbidities, laboratory data, clinical outcomes, and treatments were compared between survivors and non-survivors. We carried out univariate and multivariate logistic regression models to assess potential risk factors for in-hospital mortality. From March 10th to April 15th, 2020, 607 patients were included. Median age was 69 years interquartile range, {IQR} 22; 65% male). The most common comorbidities were hypertension (276 46·94%), diabetes (95 16·16%), chronic cardiac (133 22·62%) and respiratory (114 19·39%) diseases. 141 patients (23·2%) died. In the multivariate model the risk of death increased with older age (odds ratio, for every year of age, 1·15, 95% CI 1·11 - 1·2), tocilizumab therapy (2·4, 1·13 - 5·11), C-reactive protein at admission (1·07, per 10 mg/L, 1·04 - 1·10), d-dimer > 2·5 μg/mL (1·99, 1·03 - 3·86), diabetes mellitus (2·61, 1·19 - 5·73), and the PaO2/FiO2 at admission (0·99, per every 1 mmHg, 0·98 - 0·99). Among the prescribed therapies (tocilizumab, glucocorticoids, lopinavir/ritonavir, hydroxychloroquine, cyclosporine), only cyclosporine was associated with a significant decrease in mortality (0·24, 0·12 - 0·46; p<0·001). In a real-clinical setting, inhibition of the calcineurin inflammatory pathway, NF-κΒ, could reduce the hyperinflammatory phase in COVID-19. Our findings might entail relevant implications for the therapy of this disease and could boost the design of new clinical trials among subjects affected by severe COVID-19. Hospital Universitario Quironsalud Madrid. Own fundings for COVID-19 research.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.